B
BIOSIG TECHNOLOGIES INC
NASDAQ: BSGM (BioSig Technologies, Inc.)
Last update: 10 hours ago7.33
1.59 (27.70%)
| Previous Close | 5.74 |
| Open | 6.11 |
| Volume | 3,010,870 |
| Avg. Volume (3M) | 597,266 |
| Market Cap | 999,555,392 |
| Price / Sales | 4.73 |
| Price / Book | 76.80 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Operating Margin (TTM) | -47,726.92% |
| Diluted EPS (TTM) | -0.530 |
| Quarterly Revenue Growth (YOY) | 8.30% |
| Total Debt/Equity (MRQ) | 2.19% |
| Current Ratio (MRQ) | 2.37 |
| Operating Cash Flow (TTM) | -4.56 M |
| Levered Free Cash Flow (TTM) | -2.62 M |
| Return on Assets (TTM) | -258.22% |
| Return on Equity (TTM) | -6,342.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | BioSig Technologies, Inc. | Bullish | Bearish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.40 |
|
BioSig Technologies Inc is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP Platform (PURE EP), that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. The PURE EP Platform enables electrophysiologists to acquire raw signal data in real-time, absent unnecessary noise or interference, to maximize procedural success and minimize unnecessary inefficiencies. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 4.30% |
| % Held by Institutions | 8.81% |
| 52 Weeks Range | ||
| Median | 10.00 (36.43%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Ascendiant Capital | 06 Jun 2025 | 10.00 (36.43%) | Buy | 7.33 |
| 21 Apr 2025 | 2.50 (-65.89%) | Buy | 0.534 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AMATO ANTHONY N. | 5.05 | - | 900,000 | 4,545,000 |
| GROENEWALD FERDINAND | 5.05 | - | 175,000 | 883,750 |
| Aggregate Net Quantity | 1,075,000 | |||
| Aggregate Net Value ($) | 5,428,750 | |||
| Aggregate Avg. Buy ($) | 5.05 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AMATO ANTHONY N. | Director | 29 May 2025 | Acquired (+) | 900,000 | 5.05 | 4,545,000 |
| GROENEWALD FERDINAND | Officer | 29 May 2025 | Acquired (+) | 175,000 | 5.05 | 883,750 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |